We are live on
!
Find out more
CP
Caligan Partners Portfolio holdings
AUM
$1.5B
1-Year Est. Return
518.95%
This Fund
S&P 500
This Quarter
Est. Return
+9.22%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$79.4M
(+25%)
Cap. Flow
+$58.3M
Cap. Flow
% of AUM
14.77%
Top 10 Holdings %
Top 10 Hldgs %
94.3%
Holding
16
New
4
Increased
5
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$18.7M |
| 2 |
MRUS
Merus
MRUS
|
+$12.2M |
| 3 |
Verrica Pharmaceuticals
VRCA
|
+$8.17M |
| 4 |
Evolus
EOLS
|
+$7.02M |
| 5 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$6.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$4.34M |
| 2 |
Outlook Therapeutics
OTLK
|
+$1.7M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$1.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$7.72B
| $116M | 29.26% |
8,118,592
| – | – |
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $66.7M | 16.9% |
1,436,878
| – | – |
|
3
Exelixis
EXEL
$14.2B
| $50.8M | 12.87% |
1,525,730
| – | – |
|
|
4
Evolus
EOLS
$410M
| $29.7M | 7.53% |
2,692,388
+498,900
| +23% | +$7.02M |
|
5
Anika Therapeutics
ANIK
$202M
| $23.6M | 5.98% |
1,435,130
| – | – |
|
6
BioCryst Pharmaceuticals
BCRX
$2.48B
| $22.5M | 5.71% |
2,995,932
+412,347
| +16% | +$3.13M |
|
7
Agios Pharmaceuticals
AGIO
$2.14B
| $20.6M | 5.21% |
626,280
+46,563
| +8% | +$2.19M |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $16.6M | 4.2% |
+3,052,538
| New | +$18.7M |
|
|
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
| $13.8M | 3.51% |
1,767,982
+572,729
| +48% | +$6.98M |
|
10
Mineralys Therapeutics
MLYS
$2.38B
| $12.4M | 3.15% |
1,011,155
+30,000
| +3% | +$392K |
|
|
MRUS
11
DELISTED
Merus
MRUS
| $10.7M | 2.72% |
+255,000
| New | +$12.2M |
|
|
ABVX
12
Abivax
ABVX
$10.8B
| $5.51M | 1.39% |
+752,167
| New | +$6.92M |
|
|
13
Verrica Pharmaceuticals
VRCA
$92.8M
| $5.2M | 1.32% |
+742,969
| New | +$8.17M |
|
|
14
Enanta Pharmaceuticals
ENTA
$367M
| $1.06M | 0.27% |
184,826
-137,627
| -43% | -$1.32M |
|
|
NBP
15
NovaBridge Biosciences American Depositary Shares
NBP
$202M
| – | – |
-3,499,330
| Closed | -$4.34M |
|
|
16
Outlook Therapeutics
OTLK
$169M
| – | – |
-318,699
| Closed | -$1.7M |
|
Similar funds
BFO
JFGLC
AAM
TP
SCM
NSGL
FMI
RCW
Caligan Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Caligan Partners held 16 positions worth $395M, up 25% from $315M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Caligan Partners deployed $58.3M of net new capital in Q4 2024, opening 4 new positions and adding to 5 existing holdings. Its largest new stake was Sage Therapeutics: 3,052,538 shares worth $16.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Enanta Pharmaceuticals, an estimated $1.32M trimmed.
- Caligan Partners's largest Q4 2024 buy was Sage Therapeutics: 3,052,538 shares worth $16.6M.
- Caligan Partners added most to Evolus in Q4 2024, an estimated $7.02M increase.
- Caligan Partners's biggest Q4 2024 reduction was Enanta Pharmaceuticals, cutting an estimated $1.32M.
- Caligan Partners fully exited NovaBridge Biosciences American Depositary Shares in Q4 2024, selling an estimated $4.34M.
- Caligan Partners's ten largest holdings make up 94% of its $395M portfolio in Q4 2024.
- Caligan Partners opened 4 new positions and closed 2 in Q4 2024.
- Caligan Partners's portfolio value rose 25% quarter-over-quarter to $395M.
Based on Caligan Partners's 13F filing for Q4 2024, filed 14 Feb 2025.